ID   NZM003
AC   CVCL_D828
SY   NZM03; NZM3
DR   BioSample; SAMN07624443
DR   BioSample; SAMN14558314
DR   cancercelllines; CVCL_D828
DR   CBA; CBA-1392
DR   Cosmic; 1660299
DR   Cosmic; 2007644
DR   Cosmic; 2406331
DR   DepMap; ACH-001982
DR   Wikidata; Q54931561
RX   CelloPub=CLPUB00227;
RX   PubMed=7999427;
RX   PubMed=11216673;
RX   PubMed=20041153;
RX   PubMed=22475322;
RX   PubMed=23658559;
RX   PubMed=23755070;
RX   PubMed=24455489;
RX   PubMed=32567790;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 40.8 hours (CelloPub=CLPUB00227); 44-48 hours (CBA=CBA-1392).
CC   HLA typing: A*01:01,02:01; B*08:01,27:05; C*02:02,07:01 (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790; DepMap=ACH-001982).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Caution: The results of the Sequenom MassARRAY used in PubMed=32567790 contradicts the whole exome sequencing data for BRAF and indicates a p.Val600Lys (c.1798_1799delGTinsAA) variant.
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): CBA=CBA-1392; DepMap=ACH-001982; PubMed=32567790
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 11,13
ST   D18S51: 12,18
ST   D19S433: 12,15
ST   D21S11: 29,30.2
ST   D2S1338: 22,24
ST   D3S1358: 17
ST   D5S818: 12
ST   D7S820: 9,10 (CBA=CBA-1392; DepMap=ACH-001982)
ST   D7S820: 10 (PubMed=32567790)
ST   D8S1179: 13,14
ST   FGA: 20,22
ST   Penta D: 9
ST   Penta E: 10,14
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 21
//
RX   CelloPub=CLPUB00227;
RA   Daukste L.;
RT   "Mathematical modelling of cancer cell population dynamics.";
RL   Thesis PhD (2012), University of Canterbury, New Zealand.
//
RX   PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0;
RA   Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P.,
RA   Finlay G.J., Holdaway K.M., Baguley B.C.;
RT   "Radiosensitivity of new and established human melanoma cell lines:
RT   comparison of [3H]thymidine incorporation and soft agar clonogenic
RT   assays.";
RL   Eur. J. Cancer 30:1370-1376(1994).
//
RX   PubMed=11216673; DOI=10.3727/096504001108747620;
RA   Parmar J., Marshall E.S., Charters G.A., Holdaway K.M., Shelling A.N.,
RA   Baguley B.C.;
RT   "Radiation-induced cell cycle delays and p53 status of early passage
RT   melanoma cell lines.";
RL   Oncol. Res. 12:149-155(2000).
//
RX   PubMed=20041153; DOI=10.1371/journal.pone.0008461;
RA   Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A.,
RA   Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G.,
RA   Baguley B.C., Eccles M.R.;
RT   "A gene expression signature of invasive potential in metastatic
RT   melanoma cells.";
RL   PLoS ONE 4:E8461-E8461(2009).
//
RX   PubMed=22475322; DOI=10.1186/1471-2407-12-141;
RA   Kim J.E., Stones C.J., Joseph W.R., Leung E.Y., Finlay G.J.,
RA   Shelling A.N., Phillips W.A., Shepherd P.R., Baguley B.C.;
RT   "Comparison of growth factor signalling pathway utilisation in
RT   cultured normal melanocytes and melanoma cell lines.";
RL   BMC Cancer 12:141.1-141.10(2012).
//
RX   PubMed=23658559; DOI=10.3389/fgene.2013.00066;
RA   Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S.,
RA   Finlay G.J., Shelling A.N., Baguley B.C.;
RT   "Comparison of responses of human melanoma cell lines to MEK and BRAF
RT   inhibitors.";
RL   Front. Genet. 4:66.1-66.6(2013).
//
RX   PubMed=23755070; DOI=10.3389/fgene.2013.00097;
RA   Kim J.E., Leung E.Y., Baguley B.C., Finlay G.J.;
RT   "Heterogeneity of expression of epithelial-mesenchymal transition
RT   markers in melanocytes and melanoma cell lines.";
RL   Front. Genet. 4:97.1-97.8(2013).
//
RX   PubMed=24455489; DOI=10.3389/fonc.2013.00333;
RA   D'mello S.A.N., Flanagan J.U., Green T.N., Leung E.Y.,
RA   Askarian-Amiri M.E., Joseph W.R., McCrystal M.R., Isaacs R.J.,
RA   Shaw J.H.F., Furneaux C.E., During M.J., Finlay G.J., Baguley B.C.,
RA   Kalev-Zylinska M.L.;
RT   "Evidence that GRIN2A mutations in melanoma correlate with decreased
RT   survival.";
RL   Front. Oncol. 3:333.1-333.9(2014).
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//